Amedisys Inc (AMED) Set to Announce Quarterly Earnings on Wednesday
Amedisys Inc (NASDAQ:AMED) is set to announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of $0.53 per share for the quarter.
Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 earnings per share. On average, analysts expect Amedisys to post $2.21 EPS for the current fiscal year and $2.43 EPS for the next fiscal year.
Shares of Amedisys Inc (NASDAQ:AMED) opened at 49.54 on Wednesday. The company has a 50-day moving average of $51.54 and a 200 day moving average of $55.08. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91. The firm has a market cap of $1.68 billion, a PE ratio of 42.34 and a beta of 0.87.
A number of equities analysts have weighed in on AMED shares. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Friday, September 15th. Jefferies Group LLC restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Thursday, October 12th. SunTrust Banks, Inc. restated a “buy” rating and issued a $60.00 price target on shares of Amedisys in a report on Monday, October 9th. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Amedisys in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $56.20.
In other Amedisys news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce D. Perkins bought 2,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was acquired at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the transaction, the director now owns 15,825 shares in the company, valued at $737,445. The disclosure for this purchase can be found here. Corporate insiders own 2.00% of the company’s stock.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.